title: Biodegradable Core-Shell Copolymer-Phospholipid Nanoparticles for Combination Chemotherapy: An In Vitro Study.
abstract: In the present study, we developed novel core-shell-type lipid/particle assemblies comprising poly(lactic-co-glycolic acid) nanoparticle cores coated with a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine shell. Hydrophobic dihydroartemisinin and hydrophilic doxorubicin were co-loaded in the core-shell-type lipid/particle assemblies for combination chemotherapy. The physicochemical properties of the dual drug-loaded core-shell-type lipid/particle assemblies were characterized. The results of colorimetric cell viability assay and cellular uptake experiments demonstrated that the lipid/particle hybrid could increase the accumulation of doxorubicin accumulation in cell nuclei, thus enhancing cell cytotoxicity. This effect contributed to the high treatment efficiency of dihydroartemisinin and doxorubicin. These biodegradable lipid/polymer hybrid particles could be promising delivery systems to improve combination chemotherapy.
authors: Weicheng
authors: W
authors: Ma
authors: Airen
authors: A
authors: Xu
authors: Jingyan
authors: J
authors: Ying
authors: Bo
authors: B
authors: Li
authors: Yi
authors: Y
authors: Jin
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000031:analogs & derivatives / Q000737:chemistry; D020341:Absorbable Implants; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D037621:Artemisinins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D002467:Cell Nucleus / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects*; D004058:Diffusion; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D004343:Drug Implants; D006367:HeLa Cells; D056945:Hep G2 Cells; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016896:Treatment Outcome
chemical_list: D037621:Artemisinins; D004343:Drug Implants; D053769:Nanocapsules; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D015060:1,2-Dipalmitoylphosphatidylcholine; D019344:Lactic Acid; C039559:1,3-dipalmitoyl-2-phosphatidylcholine; C039060:artenimol; D004317:Doxorubicin